Limb Deformities, Congenital
Welcome,         Profile    Billing    Logout  
 9 Companies   8 Products   8 Products   6 Mechanisms of Action   0 Trials   59 News 


12»
  • ||||||||||  Trial completion, Enrollment change:  Thoracic Aortic Dilatation Syndromes (clinicaltrials.gov) -  May 2, 2018   
    P=N/A,  N=120, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | N=300 --> 120
  • ||||||||||  Phase classification, Enrollment change:  Studies of Heritable Disorders of Connective Tissue (clinicaltrials.gov) -  Apr 6, 2018   
    P,  N=929, Completed, 
    Active, not recruiting --> Completed | N=300 --> 120 Phase classification: P=N/A --> P | N=1335 --> 929
  • ||||||||||  Zorbtive (somatropin) / EMD Serono
    Trial completion, Enrollment change, Trial initiation date, Trial primary completion date:  Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen (clinicaltrials.gov) -  Jun 20, 2017   
    P2,  N=19, Completed, 
    Phase classification: P=N/A --> P Active, not recruiting --> Completed | N=10 --> 19 | Initiation date: Jun 2009 --> Mar 2006 | Trial primary completion date: Apr 2018 --> Jan 2017
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Clubfoot DNA Repository (clinicaltrials.gov) -  May 9, 2017   
    P=N/A,  N=379, Completed, 
    Active, not recruiting --> Completed | N=10 --> 19 | Initiation date: Jun 2009 --> Mar 2006 | Trial primary completion date: Apr 2018 --> Jan 2017 Recruiting --> Completed | N=500 --> 379 | Trial primary completion date: Jan 2018 --> May 2017
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes (clinicaltrials.gov) -  Mar 15, 2017   
    P=N/A,  N=20, Completed, 
    Recruiting --> Completed | N=500 --> 379 | Trial primary completion date: Jan 2018 --> May 2017 Recruiting --> Completed | N=100 --> 20 | Trial primary completion date: Oct 2016 --> Jul 2016
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Aortopathy in Persons With Bicuspid Aortic Valve, Turner and Marfan Syndrome (clinicaltrials.gov) -  May 24, 2016   
    P=N/A,  N=5, Completed, 
    Trial primary completion date: Mar 2016 --> Jun 2016 Recruiting --> Completed | N=60 --> 5 | Trial primary completion date: Oct 2016 --> Oct 2015
  • ||||||||||  Enrollment change, Trial withdrawal:  Instep Plantar Fasciotomy With and Without Gastrocnemius Recession (clinicaltrials.gov) -  Mar 29, 2016   
    P=N/A,  N=0, Withdrawn, 
    Recruiting --> Completed | N=60 --> 5 | Trial primary completion date: Oct 2016 --> Oct 2015 N=48 --> 0 | Recruiting --> Withdrawn
  • ||||||||||  Enrollment change, Trial termination, Trial primary completion date:  A Clinical Study of Outcomes in Foot and Ankle Bone Grafting Using map3 (clinicaltrials.gov) -  Apr 14, 2015   
    P4,  N=1, Terminated, 
    Not yet recruiting --> Recruiting N=24 --> 1 | Recruiting --> Terminated | Trial primary completion date: Jun 2016 --> Jan 2015; slow recruitment
  • ||||||||||  Trial completion:  C-Type Natriuretic Peptide and Achondroplasia (clinicaltrials.gov) -  Apr 14, 2015   
    P=N/A,  N=91, Completed, 
    N=24 --> 1 | Recruiting --> Terminated | Trial primary completion date: Jun 2016 --> Jan 2015; slow recruitment Active, not recruiting --> Completed
  • ||||||||||  Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
    Enrollment change:  Botox Clinical Trial (clinicaltrials.gov) -  Mar 18, 2015   
    P4,  N=0, Withdrawn, 
    Active, not recruiting --> Completed N=36 --> 0
  • ||||||||||  Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
    Trial completion, Trial primary completion date, HEOR, Surgery:  BOLLD: Botox Injection for Lower Extremity Lengthening and Deformity Correction Surgery (clinicaltrials.gov) -  Dec 24, 2014   
    P3,  N=125, Completed, 
    Recruiting --> Completed | N=50 --> 22 Recruiting --> Completed | Trial primary completion date: Dec 2009 --> Dec 2012
  • ||||||||||  Enrollment closed, Trial primary completion date:  Thoracic Aortic Dilatation Syndromes (clinicaltrials.gov) -  Dec 7, 2014   
    P=N/A,  N=300, Active, not recruiting, 
    Trial primary completion date: Oct 2014 --> Oct 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> May 2016
  • ||||||||||  Trial completion, Compliance:  Outcomes of Compliance With Brace Wear in Clubfoot (clinicaltrials.gov) -  Nov 24, 2014   
    P=N/A,  N=67, Completed, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> May 2016 Recruiting --> Completed
  • ||||||||||  Enrollment closed:  C-Type Natriuretic Peptide and Achondroplasia (clinicaltrials.gov) -  Oct 2, 2014   
    P=N/A,  N=100, Active, not recruiting, 
    Recruiting --> Completed Enrolling by invitation --> Active, not recruiting
  • ||||||||||  losartan / Generic mfg.
    Trial termination:  MARFANSARTAN: Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome (clinicaltrials.gov) -  Jun 18, 2014   
    P3,  N=303, Terminated, 
    Active, not recruiting --> Completed | N=50 --> 3 Active, not recruiting --> Terminated; A similar publication has been released, suggesting a beneficial effect of sartans, and only 15 patients remained to be seen for their visit at 36 months.
  • ||||||||||  Enrollment change:  Studies of Heritable Disorders of Connective Tissue (clinicaltrials.gov) -  Mar 28, 2014   
    P=N/A,  N=1335, Completed, 
    Recruiting --> Active, not recruiting N=1835 --> 1335
  • ||||||||||  Trial termination:  Ankle Equinus Contracture Treated With Dynamic Splinting (clinicaltrials.gov) -  Jul 9, 2013   
    P=N/A,  N=15, Terminated, 
    Recruiting --> Active, not recruiting Recruiting --> Terminated; Centers could not meet enrollment goals
  • ||||||||||  Enrollment change:  Ankle Equinus Contracture Treated With Dynamic Splinting (clinicaltrials.gov) -  Jul 9, 2013   
    P=N/A,  N=15, Terminated, 
    Recruiting --> Terminated; Centers could not meet enrollment goals N=50 --> 15